Test Price
2,800 AED✅ Home Collection Available
SLC35A2 Gene Glycosylation Disorder Type 2M Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Core Diagnostic Profile
This advanced genetic test provides definitive molecular diagnosis for the rare congenital disorder of glycosylation type II (CDG-II) caused by pathogenic variants in the SLC35A2 gene. Performed under ISO 9001:2015 certified processing, the assay delivers 99.9% diagnostic sensitivity via next-generation sequencing. Premium logistics include VIP mobile phlebotomy with temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM. Post-test telephonic clinical guidance is provided for result interpretation.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 certified processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The SLC35A2 NGS test detects pathogenic variants in the SLC35A2 gene responsible for congenital disorder of glycosylation type II (CDG-II). This gold-standard next-generation sequencing analysis delivers a definitive molecular diagnosis, enabling precise clinical management and informed genetic counselling.
| Feature | Our Test (NGS) | Closest Alternative (Sanger) |
|---|---|---|
| Method | Next-Generation Sequencing (NGS) with full gene coverage and CNV analysis | Single-gene Sanger sequencing, limited to coding exons |
| Diagnostic Sensitivity | 99.9% (includes deep intronic and regulatory variants) | Approximately 85–90% (misses large rearrangements and non-coding variants) |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Price in AED | 2800 | 3200–4500 |
Physician Insight & Safety Protocols
“A genetic diagnosis provides clarity, yet it must always be correlated with the full clinical picture and family history. A positive SLC35A2 result confirms CDG-II, while a negative result often prompts further investigation for other glycosylation defects. I encourage you to discuss every finding with your supervising physician.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Medication Advisory Notice
Important Clinical Reminder:
Do not discontinue any prescribed medication without consulting your doctor. Genetic test results do not replace ongoing clinical management and should be used to complement, not override, existing treatment plans.
Contraindications and Emergency Red Flags
Exclusion Criteria Requiring Immediate Attention
- Unstable acute medical condition requiring immediate hospitalisation.
- Inability to provide valid informed consent, including for minors without legal guardian consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability and UAE Federal Law No. 2 of 2019.
- Absence of pre-test genetic counselling session with mandatory pedigree documentation.
- Seek urgent emergency care if the patient develops new-onset seizures, severe metabolic acidosis, or acute neurological deterioration before sample collection.
Patient FAQ & Clinical Guidance
1. What is the purpose of this genetic test for suspected glycosylation disorder?
The test identifies the exact SLC35A2 gene mutation, confirming the CDG-II diagnosis and guiding targeted therapy, dietary management, and family planning. A precise molecular result enables your physician to tailor interventions for optimal outcomes.
2. How is the sample collected and what can I expect regarding discomfort?
A simple blood draw is taken by a trained phlebotomist at your convenience. The procedure is quick, causes minimal discomfort, and uses a paediatric gauge needle for smaller veins when necessary. Alternatively, a dried blood spot card may be used. Our VIP mobile phlebotomy service operates daily from 8 AM to 11 PM with temperature-controlled transport.
3. What happens if my result is positive for an SLC35A2 mutation?
Your doctor will explain the specific mutation's clinical impact, coordinate a multidisciplinary care plan involving genetic counselling, and offer cascade testing for at-risk relatives. A positive result provides a definitive diagnosis that can direct interventions to manage symptoms and improve quality of life.
4. Can I arrange home collection for this test?
Yes, home collection is available for this standard blood-based test. Our VIP Mobile Phlebotomy service handles sample collection at your residence daily from 8 AM to 11 PM. All samples are transported via ISO-certified cold-chain logistics to maintain specimen integrity and diagnostic accuracy.
5. What are the pre-test requirements before sample collection?
A mandatory pre-test genetic counselling session is required, including documentation of a three-generation pedigree. No fasting is necessary. You must provide valid informed consent; for minors, legal guardian consent must be obtained in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
UAE Regulatory & Data Privacy Adherence
This diagnostic service fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is handled with strict confidentiality, encrypted during transmission and storage, and accessed only by authorised medical professionals. Clinical safety and patient consent follow the provisions of Federal Decree-Law No. 4 of 2016 on Medical Liability. ISO 9001:2015 certification (INT/EGQ/2509DA/3139) reinforces our commitment to quality and regulatory excellence.
Clinical & Logistical Metadata
| Test Name | SLC35A2 Gene Glycosylation Disorder Type 2M Genetic Test (NGS) |
| Price (AED) | 2800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood, Extracted DNA, Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina NovaSeq 6000 with ACMG/AMP Guidelines |
| ICD-10-CM Code | E77.8, R62.50, Z13.71 |
| LOINC Code | 102911-8 |
| DHA Facility License & Laboratory Address | DHA License #1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians